|
Co-sponsored by
ISPOR and PhRMA Health Outcomes Committee |
|
Sunday, May 18, 2003 5:00PM-7:00PM
Crystal Gateway Marriott, Arlington, VA, USA |
|
Free. No Registration Required. |
The objective of this program is to demonstrate how managed care
organizations are utilizing pharmacoeconomic information in their
formulary decision-making process and the challenges these organizations
frequently encounter when doing so. The challenges the pharmaceutical
industry faces when providing pharmacoeconomic information to a large
number of diverse customers with varying perspectives in the U.S. will
also be presented. Different perspectives on issues related to the use of
pharmacoeconomic information by U.S. managed care organizations will be
discussed.
| 5:00-5:15 PM |
Introduction |
| |
Moderator:
Richard Willke
PhD, Senior Director, Global Outcomes Research, Pharmacia, Peapack,
NJ, USA |
| 5:15-5:45 PM |
Pharmacoeconomics: A Basis for Decision-Making |
| |
Speaker: David Berenbeim
MD, MBA, Vice President & Medical Director, Clinical Services,
Prescription Solutions, Costa Mesa, CA, USA |
| |
The importance of
pharmacoeconomic information in drug formulary decisions will be
presented. Specific focus will be on how PBMs use such information to
support formulary decisions within their organization and with their
key customers. |
| 5:45-6:15 PM |
New Directions in Pharmacy
Benefit Design and the Role of Pharmacoeconomics in Decision Making |
| |
Speaker: Kevin Donlan RPh MS, Vice President, Pharmacy Policy and Business
Development, UnitedHealthcare, Minneapolis, MN, USA |
| |
Concerns about using pharmacoeconomic information for decision making
remain. However, patient incentive based pharmacy benefit structures
provide opportunities for use of evidence based medicine and
pharmacoeconomics to inform better decision-making. |
| 6:15-6:45 PM |
Challenges and Opportunities in Providing and Communicating Pharmacoeconomic Information: A PhRMA Perspective |
| |
Speaker: Joseph DiCesare RPh, MPH, Executive Director, Health Economics
and Outcomes Research, Novartis Pharmaceuticals, East Hanover, NJ, USA |
| |
Though, in general, each segment of the U.S. healthcare system (eg.,
health plans, PBMs, physicians) uses pharmacoeconomic information in their
drug selection or formulary decision-making process, there is a wide
diversity in the extent of such utilization and type of information
considered important. Challenges the pharmaceutical industry faces in
trying to meet the pharmacoeconomic information needs of these diverse
customers will be presented. |
| 6:45-7:00
PM |
Open Discussion |
| 7:00-7:30
PM |
Reception |
|
